Entrada Therapeutics (TRDA) Stock Price, Quote, News & History | Benzinga

Entrada Therapeutics Inc (TRDA) Stock Price, Quote, News & History

TRDANASDAQ

Trade with Public

Trade with Public

$7.78

0.517.02%

At close: Aug 19, 5:00 PM EST

$7.78

N/A

After Hours: 4:00 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$7.49

Close

$7.78

Volume / Avg.

241.84K / 369.47K

Day Range

$7.40 - $7.79

52 Wk Range

5.02 - 16.45

Market Cap

$302.93M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

62

Short Interest

8.54%

Days to Cover

4.33

Recent Entrada Therapeutics, Inc. News

This HubSpot Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday

Wall Street analysts changed outlook on top names. Check all changes on analyst ratings page. See what analysts think about HUBS stock.

Avi Kapoor

Dow Dips 350 Points; US Foods Posts Downbeat Earnings

Dow falls over 100 points, S&P 500 and NASDAQ also down. Tech sector up, energy stocks down. US Foods reports lower Q1 earnings and sales. Agilon Health, Aaon, and Rackspace Technology see gains while Entrada, Fastly, and enGene Therapeutics decline. Euro zone and Asian markets mixed.

Avi Kapoor

Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why

Entrada Therapeutics stock plunged after the Duchenne trial data missed investor expectations despite positive functional improvement signals.

Vandana Singh

This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

Avi Kapoor

FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne muscular dystrophy patients.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-134.67M

Investing Cash Flow (TTM)

160.16M

Financing Cash Flow (TTM)

650.00K

Free Cash Flow (TTM)

-134.35M

Capital Expenditure (TTM)

323.00K

Net Change in Cash (TTM)

26.14M

Analyst Trends and Forecast

1

Apr

1

May

1

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$109.19M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

64.96

PB Ratio (TTM)

1.22

Earnings Yield % (TTM)

-54.36%

Earnings Yield % (FWD)

-53.26%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$5.99

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$99.28M

Debt to Equity

0.21

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$7.49

Close

$7.78

Volume / Avg.

241.84K / 369.47K

Day Range

$7.40 - $7.79

52 Wk Range

5.02 - 16.45

Market Cap

$302.93M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

62

Short Interest

8.54%

Days to Cover

4.33

About

Sector

Health Care

Industry

Biotechnology

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's E...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Entrada Therapeutics (TRDA) stock?

A

You can purchase shares of Entrada Therapeutics (NASDAQ:TRDA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Entrada Therapeutics (TRDA) competitors?

A

Other companies in Entrada Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Entrada Therapeutics (TRDA) stock?

A

Entrada Therapeutics has a consensus price target of $22.75.

Q

What is the current price for Entrada Therapeutics (TRDA)?

A

The stock price for Entrada Therapeutics (NASDAQ: TRDA) is $7.78 last updated August 19, 2026 at 4:00 PM EDT.

Q

Does Entrada Therapeutics (TRDA) pay a dividend?

A

There are no upcoming dividends for Entrada Therapeutics.

Q

When is Entrada Therapeutics (NASDAQ:TRDA) reporting earnings?

A

Entrada Therapeutics does not have any upcoming earnings scheduled.

Q

Is Entrada Therapeutics (TRDA) going to split?

A

There is no upcoming split for Entrada Therapeutics.

Q

What sector and industry does Entrada Therapeutics (TRDA) operate in?

A

Entrada Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.